DURECT (DRRX) Competitors $0.67 +0.00 (+0.02%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. IOBT, SRZN, MGNX, CLYM, CLLS, TCRX, OKYO, UNCY, PLRX, and JSPRShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include IO Biotech (IOBT), Surrozen (SRZN), MacroGenics (MGNX), Climb Bio (CLYM), Cellectis (CLLS), TScan Therapeutics (TCRX), OKYO Pharma (OKYO), Unicycive Therapeutics (UNCY), Pliant Therapeutics (PLRX), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Its Competitors IO Biotech Surrozen MacroGenics Climb Bio Cellectis TScan Therapeutics OKYO Pharma Unicycive Therapeutics Pliant Therapeutics Jasper Therapeutics IO Biotech (NASDAQ:IOBT) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends. Which has better earnings and valuation, IOBT or DRRX? DURECT has higher revenue and earnings than IO Biotech. DURECT is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIO BiotechN/AN/A-$95.49M-$1.49-1.01DURECT$2.03M10.19-$8.32M-$0.15-4.44 Is IOBT or DRRX more profitable? IO Biotech has a net margin of 0.00% compared to DURECT's net margin of -91.54%. IO Biotech's return on equity of -162.55% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets IO BiotechN/A -162.55% -125.08% DURECT -91.54%-267.36%-64.00% Do insiders & institutionals believe in IOBT or DRRX? 54.8% of IO Biotech shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 4.8% of IO Biotech shares are owned by insiders. Comparatively, 3.2% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, IOBT or DRRX? IO Biotech has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Do analysts recommend IOBT or DRRX? IO Biotech presently has a consensus price target of $9.33, indicating a potential upside of 520.16%. Given IO Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe IO Biotech is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IO Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to IOBT or DRRX? In the previous week, IO Biotech had 1 more articles in the media than DURECT. MarketBeat recorded 1 mentions for IO Biotech and 0 mentions for DURECT. IO Biotech's average media sentiment score of 0.00 equaled DURECT'saverage media sentiment score. Company Overall Sentiment IO Biotech Neutral DURECT Neutral SummaryIO Biotech beats DURECT on 10 of the 15 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.70M$2.43B$5.55B$9.05BDividend YieldN/A1.78%5.24%4.01%P/E Ratio-4.443.9219.5920.21Price / Sales10.19680.43418.25119.02Price / CashN/A158.5936.8958.10Price / Book2.304.588.035.67Net Income-$8.32M$31.34M$3.18B$249.21M7 Day Performance6.47%3.25%2.93%3.28%1 Month Performance23.69%7.08%3.75%5.55%1 Year Performance-49.11%0.17%35.20%21.09% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT0.5473 of 5 stars$0.67+0.0%N/A-47.9%$20.70M$2.03M-4.4480Gap DownIOBTIO Biotech2.6591 of 5 stars$1.30flat$9.33+617.9%+33.2%$85.64MN/A-0.9530Positive NewsSRZNSurrozen2.3965 of 5 stars$9.02-9.7%$38.50+326.8%-19.1%$85.54M$10.65M-0.3680Gap DownMGNXMacroGenics4.1302 of 5 stars$1.32+0.8%$5.71+332.9%-65.7%$82.65M$149.96M-1.48430CLYMClimb Bio2.6433 of 5 stars$1.20-0.8%$9.00+650.0%N/A$81.77MN/A-0.509CLLSCellectis3.0654 of 5 stars$1.44-2.0%$4.00+177.8%-22.7%$81.71M$49.22M-1.67290News CoverageTCRXTScan Therapeutics1.9801 of 5 stars$1.45+0.7%$7.80+437.9%-74.2%$81.49M$2.82M-1.33100Positive NewsOKYOOKYO Pharma1.8788 of 5 stars$2.19-7.6%$7.00+219.6%+145.8%$80.19MN/A0.007Positive NewsUNCYUnicycive Therapeutics3.1574 of 5 stars$7.11+12.1%$60.00+743.9%-5.4%$80.14M$680K-1.399High Trading VolumePLRXPliant Therapeutics3.9947 of 5 stars$1.25-2.3%$13.31+965.0%-88.2%$78.57M$1.58M-0.3590JSPRJasper Therapeutics1.8786 of 5 stars$5.13-0.4%$62.22+1,112.9%-68.3%$77.36MN/A-0.9820Gap Up Related Companies and Tools Related Companies IOBT Competitors SRZN Competitors MGNX Competitors CLYM Competitors CLLS Competitors TCRX Competitors OKYO Competitors UNCY Competitors PLRX Competitors JSPR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRRX Stock Alerts